Findings from an accepted manuscript published in the American Journal of Roentgenology (AJR) suggest that for patients with dense breasts undergoing screening in the incidence setting, a commercial AI tool did not provide additional benefit to mammography with supplementary ultrasound (US).

57-YO woman with dense breasts—screening mammography (not shown) assessed BI-RADS 2. a. Supplementary screening breast ultrasound performed on same day as mammogram shows 4-mm round hypoechoic mass with angular margins in right upper medial breast. b. Screenshot of output of AI tool. Tool assigned abnormality score of “low” in each breast. Ultrasound-guided core biopsy and surgery revealed invasive ductal carcinoma, not otherwise specified (Luminal A, histologic grade I). Case represents false-negative AI result. 


July 28, 2023 — Findings from an accepted manuscript published in the American Journal of Roentgenology (AJR) suggest that for patients with dense breasts undergoing screening in the incidence setting, a commercial AI tool did not provide additional benefit to mammography with supplementary ultrasound (US). 

“Mammography with supplementary ultrasound showed higher accuracy, higher specificity, and lower recall rate in comparison to mammography with AI, as well as in comparison to mammography with both US and AI,” wrote corresponding author Hee Jung Moon, MD, PhD, from the department of radiology at South Korea’s Wonju Severance Christian Hospital, Yonsei University Wonju College of Medicine. 

This AJR accepted manuscript included 1,325 women (mean age, 53 years) with dense breasts who underwent both screening mammography and supplementary breast US within a 1-month interval from January 2017 to December 2017; prior mammogram and US were available to compare in 91.2% and 91.8%, respectively. Fifteen radiologists (5 staff and 10 fellows) interpreted mammography and US examinations, and clinical reports were used for Moon et al.’s analysis. A commercially available AI algorithm (Lunit INSIGHT, v 1.1.0.0, Seoul, Korea) was used to retrospectively evaluate mammographic examinations for cancer presence. Then, screening performances were compared among mammography, AI, US, and test combinations, using generalized estimating equations. At least 24 months of imaging stability was required for a benign diagnosis. 

Ultimately, mammography with AI, mammography with US, and mammography with both ultrasound and AI showed recall rate of 14.9, 11.7, and 21.4 (all p < .05); sensitivity of 83.3%, 100.0%, and 100.0% (all p > .05); specificity of 85.8%, 89.1%, and 79.4% (all p < .05); and accuracy of 85.7%, 89.2%, and 79.5% (all p < .05). 

For more information: www.arrs.org 


Related Content

News | Radiology Business

July 25, 2024 — The radiology gender gap is decreasing, but there remains work to be done, according to an editorial ...

Time July 25, 2024
arrow
News | Digital Pathology

July 24, 2024 — Proscia, a developer of artificial intelligence (AI)-enabled digital pathology solutions for precision ...

Time July 24, 2024
arrow
News | RSNA

July 23, 2024 — Professional registration is open for RSNA 2024, the world’s largest radiology forum. This year’s theme ...

Time July 23, 2024
arrow
News | Flat Panel Displays

July 17, 2024 — LG Electronics (LG) is accelerating its B2B medical device business, expanding its lineup of diagnostic ...

Time July 17, 2024
arrow
Feature | Imaging Technology News - ITN

Be sure to check out the latest digital edition of Imaging Technology News (ITN), featuring the Mobile C-arm Systems ...

Time July 11, 2024
arrow
News | Prostate Cancer

July 11, 2024 — GE HealthCare’s MIM Software, a global provider of medical imaging analysis and artificial intelligence ...

Time July 11, 2024
arrow
Feature | Radiation Oncology | By Christine Book

News emerging from several leading organizations and vendors in the radiation therapy arena came in at a fast pace in ...

Time July 09, 2024
arrow
News | Artificial Intelligence

July 9, 2024 — Lunit, a provider of Artificial Intelligence (AI)-powered solutions for cancer diagnostics and ...

Time July 09, 2024
arrow
News | Prostate Cancer

July 5, 2024 — Lantheus Holdings, Inc., a leading radiopharmaceutical-focused company committed to enabling clinicians ...

Time July 05, 2024
arrow
Feature | Radiology Business

The ITN team wishes you a safe and happy 4th of July!

Time July 04, 2024
arrow
Subscribe Now